HCPCS Level II code J0256 designates a 10 mg vial of human alpha 1 proteinase inhibitor delivered by injection. This biologic replacement therapy is used in clinical contexts such as alpha-1 antitrypsin deficiency and represents a high-cost, specialty injectable product that impacts pharmacy and medical benefit billing nationally. Clear coding for unit dosage is important for accurate reimbursement, inventory management, and clinical documentation. Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical role, the typical sites of service where product administration occurs, and the payers commonly relevant for coverage and reimbursement considerations. The publication also outlines common billing modifiers and service-line considerations, benchmarks for coding and charge description when available, and contextual clinical background to inform coding accuracy. Data not available in the input for taxonomies, ICD-10 pairings, and related codes is noted where applicable. This summary serves as a concise reference for billing staff, revenue cycle professionals, and policy analysts who manage or review claims involving injectable alpha 1 proteinase inhibitor products.